# Curaleaf Opens Riverview Dispensary, Expanding Florida > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/curaleaf-opens-riverview-dispensary-expanding-florida-network-to-77-locations-citybiz/ > **Published:** 2026-09-04T13:21:05-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:50-04:00 > **Clinical Summary:** Curaleaf's new Riverview dispensary brings the total number of locations in Florida to 77, enhancing access to medical cannabis for patients. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchSafetyPainAnxietyMental HealthDosing Why This Matters This article matters for clinicians and their patients as it signifies an expansion of Curaleaf’s dispensaries in Florida, increasing to 77 locations. This growth in availability may improve patient access to medical cannabis products, potentially benefiting those under a physician’s care who are prescribed these treatments. Furthermore, the increased scale in the market could lead to potential improvements in product quality and variety, which can influence treatment outcomes. Clinical Summary The opening of a new dispensary by Curaleaf in Riverview, Florida, signifies an expansion of their network to 77 locations within the state. This move aims to increase scale in the medical cannabis market and broaden patient access to these products. Practical takeaway: Clinicians in Florida may find it beneficial to be aware of this growing network as it could potentially improve access for patients seeking medical cannabis treatments. Dr. Caplan’s Take “As a seasoned family physician specializing in cannabis medicine, I welcome the expansion of Curaleaf’s dispensaries in Florida. This growth not only signifies a commitment to building scale within our state’s medical cannabis market but also promises increased accessibility for patients seeking alternative treatments.” – Dr. Benjamin Caplan, MD Clinical Perspective 🌱 In the context of expanding access to medical cannabis, Curaleaf’s opening of a new dispensary in Riverview marks an important step towards increasing patient options within Florida. This growth strategy aims to enhance the company’s presence in the state’s burgeoning medical cannabis market. However, it’s crucial for healthcare providers to remain vigilant about potential confounders such as product variability and varying regulatory standards across locations. Practically, this development underscores the need for continued education and collaboration between healthcare professionals and dispensaries to ensure optimal patient care and safety in the use of medical cannabis. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Curaleaf%20Opens%20Riverview%20Dispensary%2C%20Expanding%20Florida%20Network%20to%2077%20Locations%20%7C%20citybiz%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75848)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75848)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Curaleaf%20Opens%20Riverview%20Dispensary%2C%20Expanding%20Florida%20Network%20to%2077%20Locations%20%7C%20citybiz%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D75848)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.citybiz.co/article/899086/curaleaf-opens-riverview-dispensary-expanding-florida-network-to-77-locations/](https://www.citybiz.co/article/899086/curaleaf-opens-riverview-dispensary-expanding-florida-network-to-77-locations/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) #### 📄 Printable 1-Page Physician Patient Guide Download or print Dr. Benjamin Caplan’s official clinical reference guide to share with your healthcare team. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).